The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: ReNeuron warns; Gama Aviation pledges cash return

Mon, 05th Feb 2024 20:23

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

ReNeuron Group PLC - Brigdend, Wales-based stem cell and exosomes technology company - Requests suspension of trading in company's shares. Warns company is in a highly constrained financial position and requires additional financing urgently, in order to continue as a going concern. Continues to explore a number of corporate options, including seeking to realise value for its physical and intellectual assets, but recognises that in the absence of an immediate injection of capital it needs to put staff at risk of redundancy, initiate discussions with its creditors and establish the precise solvency status of the business. Explains should it fail to achieve a solution in the short term, the board would have no option but to place the company into administration.

----------

Gama Aviation PLC - Farnborough, England-based aviation services company - Expects revenue from continuing operations for 2023 of around USD145 million, down from USD168 million in 2022. Predicts adjusted earnings before interest and tax broadly in line with expectations, despite some variances in performance across the business units. Ends year with net cash of USD82 million. Intends to make GBP16.5 million return to shareholders by a tender offer at 95 pence per share as part of a phased cash return.

----------

CEPS PLC - Bath, England-based investment company focussed on industrial sector - Reports trading for 2023 is in line with expectations which would be record results. Adds, all segments have made a solid start to 2024. Expects surplus from wound up pension scheme to total GBP537,086. Estimates receipts, net of tax will be GBP402,815, which will be received in April. Explains this will have a positive impact on the profit and loss account and balance sheet as the surplus on the scheme has not been recognised in the company's accounts. Further, plans to seek approval at a General Meeting for a share capital reduction. In addition, company is considering a recent and alleged claim from a former landlord for dilapidations and CEPS is liaising with its advisers on what it considers to be a more realistic assessment of the liability and quantum, if any.

----------

Sondrel Holdings PLC - Reading, England-based semiconductor design services provider - Confirms receipt of GBP1.5 million of payments in relation to the material turnkey application-specific integrated circuit engagement with an automotive Tier 1 supplier. Says talks with the customer over resolution of the funding for the project extension continue and additional payments are expected in the coming months, assuming completion of the 'tape out' milestone and including the balance of GBP0.2 million. Significant new ASIC business opportunities are in final negotiation for project start in early 2024 and indications remain encouraging that European and US market demand for Sondrel's turnkey ASIC services is strong, company says. Talks ongoing with suppliers to improve the terms of existing supply arrangements. Continues to seek additional capital prior to the end of March 2024 to meet short-term working capital requirements.

----------

Upland Resources Ltd - London-based oil and gas company, which has assets in Malaysia, Tunisia and the UK North Sea - Updates in relation to the Sarawak Block SK334 exploration campaign. Explains pre-drill activities have been identified and a pre-drill work program has been developed to allow early commencement of activities and expedite the drilling program.

----------

Gore Street Energy Storage Fund PLC - investor in utility-scale energy storage projects - Trading update. Reaffirms dividend target of 7% of net asset value for the financial year. Maintains a healthy balance sheet with low debt. At December 31, had GBP66 million in cash or cash equivalents. Operational fleet is on track to more than double by the end of 2024, company says.

----------

Clontarf Energy PLC - lithium and oil gas exploration and production company focused on South American and Africa - Notes the Bolivian State Lithium Co formally launched, on January 26, its second Call for Bids over seven priority salares (salt pans) in Potosi y Oruro. This includes scope for direct lithium extraction proposals and will provide a firm legal basis for work, under Bolivian laws. Says Clontarf has been encouraged to submit bids on further development of the key Uyuni, Coipasa, Pastos Grandes, Capina, Cañapa, Chiguana and Empexa salares. Further, actively participating in the priority European Union lithium initiative. This included a EU delegation to Bolivia and Argentina during November and December 2023, which included several site visits.

----------

Trident Royalties PLC - mining royalty and streaming, providing investment exposure to base, battery, precious and bulk metals - Reports quarterly receipts of USD3.2 million from exposure to gold, copper, and iron ore, a 63% increase from the third quarter, driven principally by seasonally higher deliveries from the gold off-take portfolio. Excluding the Mimbula copper royalty, receipts were slightly above the fourth quarter 2022. Says net debt at December 31 was USD22 million.

----------

Ethernity Networks Ltd - Israel-based supplier of data processing semiconductor technology for networking appliances - Further to announcement on January 31, reports the Court in Lod approved, on February 4, the proposed creditor settlement plan, details of which were announced on January 11. Following this approval, the company can now continue to undertake its business and operations as usual.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
23 Oct 2019 09:32

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

Read more
2 Oct 2019 15:15

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

Read more
21 Aug 2019 11:49

ReNeuron boosts scientific advisory board with three appointments

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced the appointment of professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel to its scientific advisory board on Wednesday.

Read more
14 Aug 2019 15:35

ReNeuron's New Cardiff University Venture Gets Research Grant

(Alliance News) - ReNeuron Group PLC on Wednesday said a new venture with Cardiff University has secured a UK government grant to research and develop new treatments for hard-to-target disorders a

Read more
14 Aug 2019 11:16

ReNeuron enters grant-funded partnership with University of Cardiff

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group is partnering with the University of Cardiff under a new grant-funded collaboration utilising its exosome-based drug delivery technology platform, it announced on Wednesday.

Read more
16 Jul 2019 12:16

ReNeuron Secures Patents For Its Exosome Technology Platform

(Alliance News) - ReNeuron Group PLC on Tuesday said it has expanded its intellectual property estate via the grant of patents, covering its exosome technology platform.The cell-based said

Read more
11 Jul 2019 11:36

ReNeuron Annual Loss Narrows On Finance Income And Licence Fee

(Alliance News) - ReNeuron Group PLC on Thursday said its loss narrowed in its most recent financial year after it received an exclusivity fee and increased finance income.Shares in were at

Read more
14 Jun 2019 15:49

ReNeuron wins 'Breakthrough of the Year' at European Mediscience Awards

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has won the 'Breakthrough of the Year' award at the 2019 European Mediscience Awards, it announced on Friday.

Read more
8 May 2019 11:19

ReNeuron Expects Annual Results In Line With Views After Progress

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday said it expects its annual results to be in line with the board's expectations as it made progress on several clinical cell-based also

Read more
8 May 2019 08:53

ReNeuron advances blindness and stroke therapy candidates

(Sharecast News) - Therapeutics outfit ReNeuron continued to trade in line with expectations throughout its recently wrapped up trading year, advancing both its human retinal progenitor cell therapy candidate and its CTX cell therapy candidate.

Read more
26 Apr 2019 12:09

ReNeuron upbeat on early data from retinitis pigmentosa trials

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced updated positive preliminary data in its ongoing phase 1 and 2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP), on Friday.

Read more
26 Apr 2019 09:58

ReNeuron Reports Positive Test Results For Blindness Treatment Therapy

LONDON (Alliance News) - ReNeuron Group PLC on Friday reported positive trial results for its human retinal progenitor cell therapy candidate for treating blindness-causing disease retinitis in up

Read more
11 Apr 2019 18:24

DIRECTOR DEALINGS: ReNeuron Chair And Other Board Members Buy Shares

LONDON (Alliance News) - ReNeuron Group PLC said a number of directors purchased shares on Thursday, including Non-Executive Chair John Berriman who bought 80,000 shares at 225 pence Thursday, in

Read more
9 Apr 2019 10:55

ReNeuron Signs Licence Deal For CTX, hRPC Cell Programmes In China

LONDON (Alliance News) - ReNeuron Group PLC on Tuesday said it has signed an exclusive licence agreement for the development, manufacture and commercialisation of its CTX and hRPC cell therapy in

Read more
4 Apr 2019 14:19

ReNeuron upbeat on progress in hRPC study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on progress with its ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease retinitis pigmentosa (RP) on Thursday, confirming that the positive efficacy seen and previously announced had, to date, been sustained in the first patient cohort in the phase 2 part of the study.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.